Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Nitsche

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Elife|July 1, 2015
Daple is a novel non-receptor GEF required for trimeric G protein activation in Wnt signalingNicolas Aznar, Krishna K Midde, Ying Dunkel, et al.
Oncotarget|October 27, 2015
VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancerChristian Schafroth, José A Galván, Irene Centeno, et al.
Oncotarget|July 13, 2014
Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 675 patientsMelina Helbling, Anne Lukesch, Aladin Haimovici, et al.
International Journal of Cancer|July 16, 2013
Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transitionPaul Roepman, Andreas Schlicker, Josep Tabernero, et al.
Clinical Epigenetics|September 28, 2018
CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathwayJanina Graule, Kristin Uth, Elia Fischer, et al.
Science Signaling|September 10, 2015
The E3 ligase RNF43 inhibits Wnt signaling downstream of mutated β-catenin by sequestering TCF4 to the nuclear membraneAnke Loregger, Martina Grandl, Raquel Mejías-Luque, et al.
Gut|February 14, 2018
Gut microbiota modulate T cell trafficking into human colorectal cancerEleonora Cremonesi, Valeria Governa, Jesus Francisco Glaus Garzon, et al.
Molecular Oncology|January 21, 2017
Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testingWolff Schmiegel, Rodney J Scott, Susan Dooley, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Elife|July 1, 2015
Daple is a novel non-receptor GEF required for trimeric G protein activation in Wnt signalingNicolas Aznar, Krishna K Midde, Ying Dunkel, et al.
Oncotarget|October 27, 2015
VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancerChristian Schafroth, José A Galván, Irene Centeno, et al.
Oncotarget|July 13, 2014
Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 675 patientsMelina Helbling, Anne Lukesch, Aladin Haimovici, et al.
International Journal of Cancer|July 16, 2013
Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transitionPaul Roepman, Andreas Schlicker, Josep Tabernero, et al.
Clinical Epigenetics|September 28, 2018
CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathwayJanina Graule, Kristin Uth, Elia Fischer, et al.
Science Signaling|September 10, 2015
The E3 ligase RNF43 inhibits Wnt signaling downstream of mutated β-catenin by sequestering TCF4 to the nuclear membraneAnke Loregger, Martina Grandl, Raquel Mejías-Luque, et al.
Gut|February 14, 2018
Gut microbiota modulate T cell trafficking into human colorectal cancerEleonora Cremonesi, Valeria Governa, Jesus Francisco Glaus Garzon, et al.
Molecular Oncology|January 21, 2017
Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testingWolff Schmiegel, Rodney J Scott, Susan Dooley, et al.
Pageof 7